Bivalent, bispecific antibodies

Patent metadata

Field	Value
Publication number	US-9266967-B2
Application number	US-33246508-A
Country	US
Kind code	B2
Filing date	Dec 11, 2008
Priority date	Dec 21, 2007
Publication date	Feb 23, 2016
Grant date	Feb 23, 2016

Abstract

The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.

First claim

The invention claimed is:

1. A bivalent, bispecific antibody, comprising:
a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein:
within the light chain of the antibody which binds to said second antigen, the variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody and the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody; and,
within the heavy chain of the antibody which binds to said second antigen, the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody, and the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody.

2. The antibody according to claim 1 ,
wherein the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface:
wherein the CH3 domain of one heavy chain is altered, so that within the interface the CH3 domain of one heavy chain that meets the interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, one or two amino acid residues are replaced with an equivalent number of amino acid residues having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain
and
wherein the CH3 domain of the other heavy chain is altered so that within the interface of the second CH3 domain that meets the interface of the first CH3 domain within the bivalent, bispecific antibody two or three amino acid residues are replaced with an equivalent number of amino acid residues having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable.

3. The antibody according to claim 2 , wherein one amino acid residue is replaced with an amino acid having a larger side chain volume, and wherein the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W).

4. The antibody according to claim 2 , wherein three amino acid residues are replaced with three amino residues having a smaller side chain volume, wherein the amino acid residues having a smaller side chain volume are independently selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).

5. The antibody according to claim 3 , wherein three amino acid residues are replaced with three amino residues having a smaller side chain volume, wherein the amino acid residues having a smaller side chain volume are independently selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).

6. The antibody according to claim 2 wherein both CH3 domains are further altered by the introduction of a cysteine (C) as an amino acid in the same residue position of each CH3 domain.

7. The antibody according to claim 3 wherein both CH3 domains are further altered by the introduction of a cysteine (C) as an amino acid in the same residue position of each CH3 domain.

8. The antibody according to claim 4 wherein both CH3 domains are further altered by the introduction of a cysteine (C) as an amino acid in the same residue position of each CH3 domain.

9. The antibody according to claim 1 , wherein one of the CH3 domains is replaced by a constant heavy chain domain CH1; and the other CH3 domain is replaced by a constant light chain domain CL.

10. A method for the preparation of an a bivalent, bispecific antibody according to claim 1 comprising the steps of
a) transforming a host cell with
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen, and
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen,

wherein:
within the light chain of the antibody which binds to said second antigen, the variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody and the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody; and,
within the heavy chain of the antibody which binds to said second antigen, the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody, and the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody;
b) culturing the host cell under conditions that allow synthesis of said antibody molecule; and
c) recovering said antibody molecule from said culture.

11. A host cell comprising:
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen, and
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein:
within the light chain of the antibody which binds to said second antigen, the variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody and the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody; and,
within the heavy chain of the antibody which binds to said second antigen, the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody, and the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody.

12. A composition comprising a bivalent, bispecific antibody according to claim 1 and at least one pharmaceutically acceptable excipient.

13. A composition comprising a bivalent, bispecific antibody according to claim 2 and at least one pharmaceutically acceptable excipient.

14. A composition comprising a bivalent, bispecific antibody according to claim 6 and at least one pharmaceutically acceptable excipient.

15. A composition comprising a bivalent, bispecific antibody according to claim 9 and at least one pharmaceutically acceptable excipient.

Assignees

• Klein Christian
• Schaefer Wolfgang
• Hoffmann La Roche

Inventors

• Klein Christian
• Schaefer Wolfgang

Classifications

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title